Autosomal dominant inheritance is a pattern in genetics in which a trait can be expressed by a person who has one relevant altered copy of a gene on an autosome—a chromosome other than a sex chromosome. In the simplest case, an individual with one disease-associated copy and one unaffected copy has a 50% probability of transmitting the disease-associated copy to each child. Transmission is possible from either parent to children of either sex, including from father to son.
The term describes a relationship between genetic variation and an observable trait, not a single biological mechanism or a uniform class of disease. Autosomal dominant conditions include skeletal disorders, inherited lipid disorders, neurological diseases, and predispositions to particular cancers. Some become apparent at birth; others emerge only in adulthood. Their expression can range from nearly uniform to highly variable, and some individuals who inherit a disease-associated variant never develop the recognized phenotype.
Understanding this inheritance pattern requires distinguishing the probability of inheriting a variant from the probability, age, and severity of disease expression. Molecular mechanisms, new mutations, mosaicism, and the limitations of genetic testing explain many departures from the familiar picture of an affected individual in every generation.
Genetic meaning and chromosomal basis
Humans ordinarily have 22 pairs of autosomes and one pair of sex chromosomes in the nuclei of their body cells. Each autosomal pair contains one chromosome inherited from the mother and one from the father. At most autosomal loci, an individual therefore has two copies of a gene. Different sequence forms at the same locus are called alleles. An individual with two different alleles is heterozygous; an individual with two identical alleles is homozygous.
Dominance concerns the phenotype of a heterozygote. For an autosomal dominant trait, a particular phenotype can occur when only one of the two alleles has the relevant effect. The term does not mean that the altered allele is more common, biologically stronger, or more likely to be transmitted than the other allele. During ordinary meiosis, the two homologous chromosomes segregate so that approximately half the gametes receive each allele. Dominance affects expression after inheritance, not the basic segregation probability.
Dominance is also specific to the phenotype being measured. A variant may behave dominantly for a clinical disorder while producing an intermediate biochemical measurement in heterozygotes. In familial hypercholesterolemia caused by certain LDLR variants, for example, one altered copy can substantially increase circulating low-density lipoprotein cholesterol, whereas pathogenic variants affecting both copies generally produce a more severe phenotype. The clinical classification as dominant does not imply that individuals with one and two altered copies are equivalent.
An autosomal location generally permits transmission through either sex without the characteristic restrictions of sex-linked inheritance. Nevertheless, equal transmission probability does not guarantee equal disease frequency or severity in males and females. Hormonal influences, anatomy, environmental exposures, and sex-specific expression can alter the phenotype. A predisposition affecting an organ present mainly in one sex may pass through an individual who has no corresponding organ-specific disease.
Autosomal dominance is therefore a statement about a specified genetic variant, phenotype, and biological context. It is not always an immutable property of an entire gene. Different variants in one gene can cause dominant and recessive disorders through different mechanisms. Conversely, clinically similar dominant conditions may result from variants in several different genes. Distinguishing the location of the variant, its molecular effect, and the trait being classified prevents these separate meanings from being conflated.
Molecular mechanisms of dominance
Several molecular mechanisms can make one altered gene copy sufficient to produce a phenotype. In haploinsufficiency, the functional output from a single unaffected copy is insufficient for normal biological activity. This is especially important for dosage-sensitive developmental regulators and structural components. A deletion, premature stop variant, or disruption of RNA processing may reduce the amount of functional product. In some cases, degradation of the altered transcript by nonsense-mediated decay helps explain why little or no abnormal protein is produced.
A second mechanism is a dominant-negative effect, in which an altered product interferes with the product made by the unaffected allele. This can occur when a protein functions as a multimer or participates in a larger structural assembly. Some pathogenic variants in the genes encoding type I collagen produce abnormal chains that enter collagen molecules and compromise their structure. Certain forms of osteogenesis imperfecta illustrate this mechanism. Other variants in the same collagen genes reduce protein quantity instead, showing why variant type can influence severity.
In a gain-of-function mechanism, the altered product has increased activity, remains active when it should be switched off, or acquires an abnormal function. Achondroplasia usually results from activating variants in FGFR3, which encodes a receptor involved in skeletal development. Excessive signaling inhibits the normal growth of cartilage that contributes to long-bone formation. The phenotype is not caused by a simple shortage of receptor protein; it reflects inappropriate receptor activity.
Other dominant disorders involve toxic effects. In Huntington disease, expansion of a CAG repeat in HTT produces an elongated polyglutamine tract in huntingtin. The altered protein disrupts several cellular processes and contributes to progressive neuronal dysfunction. Dominant neurological disorders can also result from altered ion channels, in which changes in opening, closing, or ion conductance disturb electrical activity. Such effects may occur without a large change in the amount of protein present.
Inherited cancer predispositions introduce an important distinction between organismal and cellular dominance. A person with one germline pathogenic variant in a tumor suppressor gene may have a dominantly inherited predisposition, while a particular cell commonly requires an additional somatic alteration affecting the remaining functional copy before tumor development. This principle underlies the two-hit hypothesis. The inherited susceptibility is dominant in a pedigree even when loss of both functional copies is important within the tumor cell. Thus, no single biochemical rule accounts for every autosomal dominant condition.
Pedigree patterns and transmission probabilities
A typical autosomal dominant pedigree shows vertical transmission: affected individuals occur in successive generations, and an affected person often has an affected parent. Both sexes can transmit the trait. Father-to-son transmission is particularly useful evidence against an X-linked explanation, because a father ordinarily gives his son a Y chromosome rather than his X chromosome. These observations are clues rather than proof; small families, incomplete clinical information, and variable expression can obscure the pattern.
For a simple model, let represent a dominant disease-associated allele and an allele not associated with that condition. A heterozygous parent, , and a parent with genotype produce the following probabilities for each conception:
The 50% figure concerns transmission of the allele. It equals the probability of disease only when the relevant genotype reliably produces the specified phenotype over the time period considered. It also assumes that neither parent has an additional relevant variant and that unusual factors such as parental germline mosaicism do not alter the model.
Successive transmissions are ordinarily treated as independent events. Three children who inherit the familial variant do not make inheritance less likely in a fourth child. Under the simple heterozygous-parent model, the number of children inheriting the variant among children follows a binomial distribution:
Consequently, the probability that at least one of four children inherits the variant is . This does not mean that a family of four must include an affected child, nor that exactly half the children in each family will inherit the variant.
When both parents are heterozygous for the same dominant allele, the elementary genotype probabilities are one-quarter , one-half , and one-quarter . The corresponding clinical outcomes depend on the condition. For some disorders, two altered copies cause a much more severe phenotype or markedly reduced survival; for others, the effects are less sharply separated. In achondroplasia, the homozygous state usually causes a severe, life-limiting skeletal disorder. These genotype proportions describe conceptions under the model and need not equal proportions among live births.
More complex parental genotypes require different calculations. Two affected parents may have variants in different genes, or different pathogenic variants in the same gene. The inheritance pattern alone does not establish whether their offspring could inherit both conditions or a biallelic disorder. Reliable probability calculations therefore depend on the actual genetic explanation, not only on whether both parents appear affected.
Penetrance, expressivity, and age at onset
Penetrance is the proportion of individuals with a specified genotype who express a defined phenotype. Complete penetrance means that all individuals with that genotype express the phenotype under the conditions and age range being considered. Reduced penetrance means that some do not. Penetrance is distinct from the 50% transmission probability: an allele can segregate normally even when its consequences are not clinically apparent in every person who inherits it.
Age is often essential to the definition. A child carrying a pathogenic variant for an adult-onset disorder may be unaffected because the disease has not yet developed, not because the variant will remain nonpenetrant throughout life. Huntington disease provides a well-characterized example. HTT alleles containing 36–39 CAG repeats have reduced penetrance, whereas alleles with 40 or more repeats are generally considered fully penetrant over a normal lifespan. Even within these categories, repeat length does not specify an exact age of onset.
Variable expressivity describes differences in the manifestations or severity of a condition among individuals who express it. Neurofibromatosis type 1 can involve café-au-lait macules, skin-fold freckling, neurofibromas, learning difficulties, skeletal abnormalities, and other findings in different combinations. Two relatives with the same familial NF1 variant may differ substantially in their clinical features. Recognizing that the variant is present therefore does not establish the full future phenotype.
Variation can arise from the particular pathogenic allele, genetic background, environmental influences, developmental events, and stochastic cellular processes. Modifier genes may alter the consequences of a primary variant without being sufficient to cause the disorder on their own. Tissue-specific gene expression and biological thresholds can also matter: a reduction in functional protein may be tolerated in one tissue but not another. Some differences between relatives remain unexplained even after the principal pathogenic variant has been identified.
These distinctions change how family histories are interpreted. An apparently unaffected parent may carry a familial variant with reduced penetrance, have subtle manifestations, or be younger than the usual age of onset. A pedigree can therefore appear to skip a generation without any departure from autosomal transmission. Conversely, a relative with a superficially similar phenotype may have an unrelated cause, sometimes called a phenocopy. Penetrance estimates also depend on study design: families recruited through specialist clinics may overrepresent severe manifestations, while population-based sequencing can identify individuals with milder or previously unrecognized expression.
New variants and mosaicism
An autosomal dominant condition does not require an affected parent. A disease-associated mutation can arise for the first time in a parental egg or sperm, in a precursor of those cells, or after fertilization. Such a change is described as de novo when it is newly identified in the affected individual rather than inherited as a constitutional variant from a parent. If present constitutionally in a heterozygous individual, it can subsequently be transmitted to that person's children with the usual approximately 50% probability.
De novo variants are especially important in disorders that substantially reduce reproductive fitness or frequently result from particular recurrent nucleotide changes. Many cases of achondroplasia arise de novo. Its association with increased paternal age has a specific biological component: some activating variants in the fibroblast growth factor receptor signaling pathway confer a selective advantage on mutant spermatogonial cells. Expansion of these cell lineages can increase their representation in sperm as a man ages. This mechanism is more specific than a general accumulation of random copying errors.
Mosaicism occurs when genetically distinct cell populations arise from one fertilized egg. A postzygotic variant may be present in only some tissues or in only a fraction of cells within a tissue. Its effects depend on the timing of the mutation, the affected developmental lineage, and the gene involved. A person may have localized or segmental manifestations rather than the generalized phenotype associated with a constitutional heterozygous variant.
Parental germline mosaicism is particularly important for recurrence. A parent may have a pathogenic variant in some egg or sperm precursors while having no detectable variant in blood and no recognizable phenotype. More than one child can consequently inherit the same variant even though routine parental testing is negative. Negative blood testing does not establish that every germ cell lacks the variant. Conversely, a low-level variant detected in blood does not by itself specify its proportion in reproductive cells.
Somatic and germline involvement can overlap. A parent with mild manifestations may have the variant in both body tissues and part of the germline; an affected child may inherit it constitutionally and have more extensive disease. There is no universal recurrence probability for all mosaic situations. It depends on the disorder, the tissues involved, available molecular findings, and empirical observations. These mechanisms explain why an isolated case is not evidence against autosomal dominant inheritance and why the simple 50% model cannot be applied indiscriminately to every mosaic individual.
Clinical diversity and genotype–phenotype relationships
Autosomal dominant conditions affect many biological systems because dominance can arise through numerous molecular pathways. Marfan syndrome, usually caused by pathogenic variants in FBN1, affects connective tissues and can involve the aorta, eyes, and skeleton. Fibrillin-1 contributes to extracellular microfibrils and influences signaling as well as tissue architecture. Variation in the affected molecular region and the type of sequence change helps explain some clinical differences, although prediction from genotype remains incomplete.
Familial hypercholesterolemia illustrates a disorder in which a measurable biochemical phenotype connects inheritance to disease risk. Dominant forms are associated with pathogenic variants in genes including LDLR, APOB, and PCSK9. These can impair receptor-mediated clearance of low-density lipoprotein or alter receptor regulation, producing elevated LDL cholesterol from early life. Biallelic LDLRAP1-related hypercholesterolemia, by contrast, is generally recessive. A shared clinical label can therefore encompass genetically distinct inheritance mechanisms.
Autosomal dominant polycystic kidney disease commonly involves PKD1 or PKD2. Progressive cyst development can enlarge the kidneys and impair function, while manifestations can also occur outside the kidneys. The inherited variant creates susceptibility throughout relevant tissues, but cyst formation involves additional cellular events and is not simply an identical response in every kidney cell. Gene-level and variant-level differences contribute to differences in typical disease course, with considerable variation among individuals.
Dominant neurological disorders range from developmental syndromes to late-onset degeneration. Huntington disease is characterized by progressive motor, cognitive, and psychiatric manifestations, whereas certain dominant channel disorders produce episodic symptoms such as attacks of muscle weakness or seizures. In these conditions, a relatively specific disturbance of cellular physiology can have system-wide consequences. A change in the behavior of an ion channel, for example, can alter the threshold for electrical activity without visibly changing tissue structure at first.
Some dominant disorders are inherited predispositions rather than diseases that occur inevitably. Pathogenic variants in BRCA1 or BRCA2 confer increased susceptibility to particular cancers, but inheritance does not mean that every person will develop cancer or develop the same tumor type. Somatic events and other factors influence whether and where a malignancy arises. This distinction between inheriting a predisposition and inheriting a fully expressed disease is central to accurate description.
Genotype–phenotype relationships are therefore probabilistic and condition-specific. Even a firmly established pathogenic variant may predict a disease category more reliably than its timing, severity, or full range of manifestations. Conversely, the same gene can be associated with clinically distinct disorders when different variants cause different functional effects.
Repeat expansions, anticipation, and parent-of-origin effects
Genetic anticipation is the tendency for a disorder to appear at an earlier age, or sometimes with greater severity, in successive generations. It is not a universal property of autosomal dominant inheritance. In several well-characterized disorders, it results from unstable repeated sequences in DNA that can expand during transmission. The child may inherit an allele containing more repeat units than the parent's allele, and the larger expansion can change the phenotype.
Huntington disease provides a prominent example. Its CAG expansion occurs within the coding region of HTT, and larger expansions are generally associated with earlier onset. Repeat instability is particularly important during paternal transmission, and very large expansions associated with juvenile-onset disease are more often inherited from the father. Nevertheless, repeat number is not a precise clock. Other genetic factors, somatic repeat expansion, and additional biological influences contribute to variation in onset.
Myotonic dystrophy demonstrates that repeat expansions can act through RNA rather than solely through an abnormal protein. Type 1 results from a CTG expansion in the noncoding region of DMPK. The expanded repeat is transcribed into RNA that disrupts the activity of RNA-binding proteins, leading to abnormalities in RNA splicing across multiple genes. This contributes to a multisystem phenotype involving muscle and other organs. The severe congenital form is predominantly associated with maternal transmission.
Myotonic dystrophy type 2 is caused by a CCTG expansion in CNBP. It is also autosomal dominant, but it does not reproduce all the clinical and transmission features of type 1. The comparison illustrates why “repeat-expansion disorder” is not a complete explanation of inheritance behavior. Repeat sequence, genomic location, transmission stability, and molecular consequences all matter. Expansion may also occur within somatic tissues during life, so repeat length measured in blood may not fully represent repeat lengths in other organs.
Parent-of-origin effects can additionally arise through genomic imprinting, an epigenetic process in which gene expression depends on whether an allele was inherited from the mother or father. Such effects are distinct from ordinary autosomal dominance, although they can modify the appearance of some autosomal disorders. Parent-specific repeat instability and imprinting are separate mechanisms and should not be treated as interchangeable.
Apparent anticipation can also result from ascertainment. Once a disorder has been recognized in a family, younger relatives may be examined earlier and diagnosed sooner. Small pedigrees may preferentially capture striking parent–child differences. Demonstrating biological anticipation therefore requires more than observing earlier diagnosis in a few successive generations; molecular evidence of repeat instability has been particularly important in establishing it.
Historical development and gene discovery
The conceptual basis of dominant inheritance emerged from Gregor Mendel's experiments with peas, presented in 1865 and published in 1866. Mendel distinguished traits expressed in hybrids from traits that reappeared after segregation in later generations. His work did not identify DNA or chromosomes as the physical basis of inheritance, but it established a framework in which discrete hereditary factors could be transmitted without blending permanently together.
Human pedigrees subsequently provided evidence for comparable patterns. In 1872, George Huntington published a description of hereditary chorea that emphasized familial transmission, adult onset, and characteristic clinical features. The condition later named Huntington disease became a major example of autosomal dominant inheritance. Early descriptions could identify the family pattern without knowing the causative gene, and family histories remained central to recognition long before molecular testing was possible.
In the early twentieth century, the chromosome theory of inheritance connected Mendelian segregation with chromosome behavior. Human genetics nevertheless advanced slowly because family sizes were limited, generations were long, and controlled crosses were impossible. The establishment in 1956 that the usual human chromosome number is 46 strengthened the cytogenetic framework. Pedigree analysis and biochemical investigation could then be integrated with an increasingly accurate account of human chromosomes.
Genetic linkage analysis made it possible to locate disease-associated regions by following DNA markers through families. Markers close to a disease locus tend to be inherited with it because crossing over separates nearby sites less frequently than distant ones. In 1983, a polymorphic DNA marker was linked to the Huntington disease locus on chromosome 4. In 1993, the expanded CAG repeat in the gene now called HTT was identified. This progression—from pedigree to chromosomal region to molecular lesion—became a landmark example of positional gene discovery.
Other dominant disorders connected inheritance to cellular physiology. Work on familial hypercholesterolemia by Michael Brown, Joseph Goldstein, and colleagues established the importance of the LDL receptor in cholesterol metabolism. Their discoveries concerning cholesterol regulation were recognized with the 1985 Nobel Prize in Physiology or Medicine. This research showed how a dominant clinical phenotype could reveal a receptor-mediated pathway with significance beyond the affected families.
The development of DNA sequencing, and later high-throughput sequencing, changed the scale of investigation. Researchers could compare large numbers of genes, identify de novo variants by sequencing parent–child trios, and study dominant conditions in families too small for traditional linkage analysis. These methods expanded the number of recognized disorders while also revealing more incomplete penetrance and phenotypic diversity than classic pedigrees alone had suggested.
Molecular diagnosis and interpretation
Investigation of a suspected autosomal dominant condition combines phenotype, family history, and molecular evidence. A multigenerational pedigree records affected and apparently unaffected relatives, ages, relevant manifestations, and relationships. These details help distinguish a dominant model from recessive, sex-linked, mitochondrial, or non-Mendelian explanations. Clinical similarity alone is insufficient: unrelated disorders may share features, while one familial disorder may look different in different relatives.
The appropriate molecular method depends on the type of variant under consideration. Sequencing can detect many single-nucleotide changes and small insertions or deletions. Deletion and duplication analysis detects larger losses or gains that some sequencing approaches may miss. Repeat-expansion disorders often require specifically designed assays because conventional short-read methods may not measure long or structurally complex repeats reliably. Suspected mosaicism introduces additional questions about sequencing depth, assay sensitivity, and which tissue is tested.
A detected variant must be interpreted rather than merely reported as different from a reference sequence. Evidence includes its frequency in population databases, predicted and demonstrated functional effects, segregation within families, previous observations in affected individuals, and whether the gene has a well-established relationship to the phenotype. The patient's genotype must also fit the known disease mechanism. For example, a protein-truncating variant is not automatically pathogenic in a gene whose relevant dominant disorder is caused specifically by activating changes.
Clinical laboratories commonly use categories including pathogenic, likely pathogenic, uncertain significance, likely benign, and benign. A variant of uncertain significance does not establish a molecular diagnosis. Family segregation can contribute evidence, but it must be evaluated in light of age-dependent penetrance, phenocopies, and the number of informative relatives. Functional experiments can also be valuable, provided that the assay meaningfully represents the biological mechanism rather than merely showing some measurable difference.
When a familial pathogenic variant is known, targeted testing can establish whether a relative inherited it. This can be more direct than testing linked markers, which infer inheritance through nearby DNA and can be complicated by recombination. A positive result establishes the presence of the variant but may not predict severity or age at onset. A negative result for the established familial variant generally excludes that particular inherited molecular cause, not every possible cause of similar symptoms.
Interpretation can change as evidence accumulates. Newly characterized disease mechanisms, larger population datasets, and additional family observations can support reclassification. Ethical issues include informed consent, the handling of findings unrelated to the original investigation, testing for adult-onset conditions, and protection of genetic information. Because a result may reveal information about relatives as well as the tested individual, molecular diagnosis also intersects with family communication and data privacy.